scholarly journals Asymmetric syntheses of (+)- and (–)-collybolide enable reevaluation of kappa-opioid receptor agonism

Author(s):  
Sophia Shevick ◽  
Stephan Freeman ◽  
Guanghu Tong ◽  
Robin Russo ◽  
Laura Bohn ◽  
...  

The fungal metabolite collybolide attracted attention as a non-nitrogenous, potent and biased agonist of the kappa-opioid receptor (KOR). Here we report a 10-step asymmetric synthesis of this complex sesquiterpene that enables facile access to either enantiomer. The synthesis relies on a diastereoselective α-benzoyloxylation to install the buried C6 benzoate and avoid irreversible translactonization of the congested, functionally dense core. Neither enantiomer, however, exhibited KOR agonism, indicating that collybolide has been mischaracterized as a KOR agonist and leaving open the basis for antipruritic effects in mice.

2021 ◽  
Author(s):  
Sophia Shevick ◽  
Stephan Freeman ◽  
Guanghu Tong ◽  
Robin Russo ◽  
Laura Bohn ◽  
...  

The fungal metabolite collybolide attracted attention as a non-nitrogenous, potent and biased agonist of the kappa-opioid receptor (KOR). Here we report a 10-step asymmetric synthesis of this complex sesquiterpene that enables facile access to either enantiomer. The synthesis relies on a diastereoselective α-benzoyloxylation to install the buried C6 benzoate and avoid irreversible translactonization of the congested, functionally dense core. Neither enantiomer, however, exhibited KOR agonism, raising the specter of a yet-unidentified contaminant responsible for the reported activity.


2017 ◽  
Vol 60 (7) ◽  
pp. 3070-3081 ◽  
Author(s):  
Zhong Zheng ◽  
Xi-Ping Huang ◽  
Thomas J. Mangano ◽  
Rodger Zou ◽  
Xin Chen ◽  
...  

Planta Medica ◽  
2015 ◽  
Vol 81 (05) ◽  
Author(s):  
PR Polepally ◽  
A Keasling ◽  
K White ◽  
E Vardy ◽  
BL Roth ◽  
...  

2020 ◽  
Author(s):  
Samuel David Clark

AbstractThe kappa opioid receptor (KOR) and its endogenous ligands dynorphins (DYN) have been implicated in the development or symptomatology of a variety of neuropsychiatric disorders. This review covers a brief history of the development of KOR agonists and antagonists, their effects in healthy volunteers, and the potential role of DYN/KOR dysfunction in schizophrenia and major depressive disorder from a translational perspective. The potential role of DYN/KOR dysfunction in schizophrenia is based on several lines of evidence. Selective KOR agonists induce affective states in healthy volunteers with similarities to the symptoms of schizophrenia. Studies have shown increased DYN in patients with schizophrenia, although the data have been mixed. Finally, meta-analytic data have shown that opioid antagonists are associated with reductions in the symptoms of schizophrenia. The potential role of DYN/KOR dysfunction in major depressive disorder is also based on a combination of preclinical and clinical data. Selective KOR agonists have shown pro-depressive effects in human volunteers, while selective KOR antagonists have shown robust efficacy in several preclinical models of antidepressant activity. Small studies have shown that nonselective KOR antagonists may have efficacy in treatment-resistant depression. Additionally, recent clinical data have shown that the KOR may be an effective target for treating anhedonia, a finding relevant to both schizophrenia and depression. Finally, recommendations are provided for translating preclinical models for schizophrenia and major depressive disorder into the clinic.


2021 ◽  
Vol 185 ◽  
pp. 108456
Author(s):  
Matthew Hein ◽  
Guangchen Ji ◽  
Dalton Tidwell ◽  
Preston D'Souza ◽  
Takaki Kiritoshi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document